Journal article
Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart
DJ Campbell, Y Zhang, DJ Kelly, RE Gilbert, DJ McCarthy, W Shi, GK Smyth
Clinical and Experimental Pharmacology and Physiology | Published : 2011
Abstract
1. Aliskiren is a renin inhibitor with an IC50 of 0.6nmol/L for human renin, 4.5nmol/L for mouse renin and 80nmol/L for rat renin. 2. In the present study, we compared the effects of aliskiren (10mg/kg per day), the angiotensin-converting enzyme inhibitor perindopril (0.2mg/kg per day) and their combination on angiotensin and bradykinin peptides in female heterozygous (mRen-2)27 rats, transgenic for the mouse renin gene. 3. All three treatments produced similar reductions in systolic blood pressure, heart weight and plasma aldosterone levels and reduced angiotensin II levels in lung, but only perindopril and the combination reduced angiotensin II levels in kidney of (mRen-2)27 rats. In contr..
View full abstractRelated Projects (1)
Grants
Awarded by National Health and Medical Research Council of Australia (NHMRC)
Funding Acknowledgements
This work was funded by a program grant from the Juvenile Diabetes Research Foundation, the National Health and Medical Research Council of Australia (NHMRC) and research grants from Novartis Institutes for Biomedical Research. DC (Grant ID 395508), DK (Grant ID 566867) and GS (Grant ID 575515) are recipients of Senior Research Fellowships from the NHMRC. DC, DK and RG have received grants from Novartis Institutes of Biomedical Research and DC and RG have been members of advisory boards for Novartis. The authors thank Mariana Pacheco and Jemma Court for expert technical assistance.